Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Net Margin (2019 - 2026)

ADC Therapeutics has reported Net Margin over the past 8 years, most recently at 164.57% for Q1 2026.

  • Quarterly results put Net Margin at 164.57% for Q1 2026, up 60747.0% from a year ago — trailing twelve months through Mar 2026 was 219.01% (down 1547.0% YoY), and the annual figure for FY2021 was 732.68%, changed.
  • Net Margin reached 164.57% in Q1 2026 per ADCT's latest filing, up from 260.1% in the prior quarter.
  • Across five years, Net Margin topped out at 372.3% in Q2 2022 and bottomed at 772.04% in Q1 2025.
  • Median Net Margin over the past 5 years was 82.45% (2023), compared with a mean of 123.74%.
  • The largest annual shift saw Net Margin tumbled -155773bps in 2022 before it soared 60747bps in 2026.
  • Over 5 years, Net Margin stood at 0.0% in 2022, then tumbled by -952988bps to 0.33% in 2023, then plummeted by -73449bps to 242.61% in 2024, then dropped by -7bps to 260.1% in 2025, then skyrocketed by 37bps to 164.57% in 2026.
  • Business Quant data shows Net Margin for ADCT at 164.57% in Q1 2026, 260.1% in Q3 2025, and 300.68% in Q2 2025.